What are the responsibilities and job description for the Co-op Biology-Oncology position at BioSpace?
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations.
On August 8th 2025, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER ), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant.
In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024.
#TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say.
For more information, please visit www.arvinas.com.
Position Summary
The Spring 2026 Oncology Biology Co-Op position at Arvinas will focus on evaluating the effect of novel heterobifunctional degrader molecules on intracellular oncology targets and on validating newly proposed targets for potential degrader discovery efforts. This position will involve cell biology and molecular biology techniques, and potentially new target proposition workflows. The candidate will join a collaborative, multi-disciplinary team of biologists, biochemists, biophysicists, and chemists. This is a laboratory-based role dedicated to validating novel oncology targets through functional and mechanistic studies, including the design and execution of in vitro cellular assays to establish the biological rationale for PROTAC-based therapeutic approaches. We are looking for a passionate and highly motivated individual who is enthusiastic about novel therapeutic applications, such as degraders, and wants to contribute to exploring new targets for degradation in the oncology space.
This training opportunity allows the individual to learn the process of early drug discovery in a collaborative environment.
This position reports to a Senior Research Investigator, Biology, Oncology and will be located at our headquarters in New Haven, CT.
Principal Responsibilities
Key responsibilities of this role include, but are not limited to:
In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations.
On August 8th 2025, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER ), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant.
In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024.
#TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say.
For more information, please visit www.arvinas.com.
Position Summary
The Spring 2026 Oncology Biology Co-Op position at Arvinas will focus on evaluating the effect of novel heterobifunctional degrader molecules on intracellular oncology targets and on validating newly proposed targets for potential degrader discovery efforts. This position will involve cell biology and molecular biology techniques, and potentially new target proposition workflows. The candidate will join a collaborative, multi-disciplinary team of biologists, biochemists, biophysicists, and chemists. This is a laboratory-based role dedicated to validating novel oncology targets through functional and mechanistic studies, including the design and execution of in vitro cellular assays to establish the biological rationale for PROTAC-based therapeutic approaches. We are looking for a passionate and highly motivated individual who is enthusiastic about novel therapeutic applications, such as degraders, and wants to contribute to exploring new targets for degradation in the oncology space.
This training opportunity allows the individual to learn the process of early drug discovery in a collaborative environment.
This position reports to a Senior Research Investigator, Biology, Oncology and will be located at our headquarters in New Haven, CT.
Principal Responsibilities
Key responsibilities of this role include, but are not limited to:
- Cell culture including sterile technique for mammalian cell lines
- Functional genomics approaches (such as CRISPR KO, siRNA/shRNA KD) to interrogate targets to understand their biological function, especially at scale or in a hypothesis-driven way
- Cellular assays to monitor activity of degrader compounds (such as Western blot, JESS, high-content imaging, HiBiT, NanoBRET)
- Establishing and developing new assays to detect target engagement and small molecule binding to targets in vitro and in cells
- Data analysis and interpretation, as well as presenting data in team meetings.
- Meeting with key stakeholders outside of the project team to devise future experiments for downstream applications
- The candidate should be a highly motivated fast learner with flexibility and ability to multi-task, as well as a good lab citizen.
- Experience in cell culture is required.
- Experience with immunoblotting and genetic perturbation assay skills are required.
- Prior lab experience highly preferred.
- Previous oncology experience is preferred
- Knowledge of ubiquitin-based proteasomal degradation is desired, but not a pre-requisite.
- Experience in the computational analysis and interpretation of omics datasets, such as RNA-seq and proteomics, to inform biological hypotheses, target identification, and mechanistic understanding is considered a plus.
- Ability to work full-time (40 hours per week).
- Arvinas will not be providing VISA sponsorship for this position now or in the future. You must have the ability to work without a need for a current or future VISA sponsorship.
- The duties of this role are generally conducted in a lab environment. Employees must be able, with or without an accommodation to lift/carry 15/30 pounds unassisted/assisted; work comfortable in a controlled environment with and around biological, infectious and hazardous materials; gown/degown PPE; use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours.
- Preference to Master’s / PhD student currently enrolled in a program with a concentration in cell biology, immunology, pharmacology, biology, or related fields.